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Summary Seizures do not occur randomly. They tend to cluster in the majority of
men and women with epilepsy. Seizure clusters, in turn, often show a periodicity.
When the periodicity of seizure exacerbation aligns itself with that of the menstrual
cycle, it is designated as catamenial epilepsy. The neuroactive properties of repro-
ductive steroids and the cyclic variation in their serum concentrations are important
pathophysiologic factors. Recent investigations have demonstrated and confirmed the
existence of at least three patterns of catamenial seizure exacerbation: perimenstr-
ual and periovulatory in ovulatory cycles and entire luteal phase in anovulatory
cycles. A rational mathematical basis for the categorization of seizure exacerbation as
catamenial epilepsy has been developed. It identifies approximately one third of
women as having catamenial epilepsy. If seizures show hormonal sensitivity in their
occurrence, they may also respond to hormonal treatment. Successful open label
trials using cyclic natural progesterone supplement, depomedroxyprogesterone and
gonadotropin-releasing hormone analogues in women and using testosterone with or
without aromatase inhibitor in men have been reported. Prospective, randomized,
placebo-controlled, double-blind investigations are warranted and under way.
# 2007 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.Definition, patterns and prevalence
Seizures do not occur randomly in the majority of
men and women with epilepsy.1 They tend to cluster
in over 50% of cases.1,2 Seizure clusters, in turn, may
occur with temporal rhythmicity in a significant
proportion of men (29%) and women (35%) with
epilepsy.3 When the periodicity of seizure exacer-
bation aligns with the menstrual cycle, it is com-
monly known as catamenial epilepsy.4 This may be* Tel.: +1 781 431 0277; fax: +1 781 431 0274.
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doi:10.1016/j.seizure.2007.11.014attributable to (1) the neuroactive properties of
steroid hormones and (2) the cyclic variation in their
serum levels.4
Physiological endocrine secretion during the
menstrual cycle influences the occurrence of sei-
zures (Fig. 1). In ovulatory cycles, seizure frequency
shows a statistically significant positive correlation
with the serum estradiol/progesterone ratio.5 This
ratio is highest during the days prior to ovulation and
menstruation and is lowest during the early- and
mid-luteal phase.5 The premenstrual exacerbation
of seizures has been attributed to the rapid with-
drawal of the antiseizure effects of progesterone.4,5. Published by Elsevier Ltd. All rights reserved.
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Figure 1 Three patterns of catamenial epilepsy: perimenstrual (C1) and periovulatory (C2) exacerbations during
normal ovulatory cycles and entire second half of the cycle (C3) exacerbation during inadequate luteal phase cycles
where Day 1 is the first day of menstrual flow and Day 14 is the day of ovulation.Mid cycle exacerbations may be due to the preovu-
latory surge of estrogen, unaccompanied by any rise
in progesterone until ovulation occurs.4—6 Seizures
are least common during the mid-luteal phase when
progesterone levels are highest4—6 except in anovu-
latory cycles in which the mid cycle surge in estro-
gen still occurs, albeit not as high as in ovulatory
cycles, but unaccompanied by any substantial
increase in progesterone levels.4
Herzog et al.4,7 have presented statistical evi-
dence to support the concept of catamenial epilepsy
and the existence of at least three distinct patterns
of seizure exacerbation in relation to the menstrualcycle (Fig. 1): (1) perimenstrual (C1: Days 3 to 3)
and (2) periovulatory (C2: Days 10 to13) in normal
cycles, and (3) luteal (C3: Days 10—3) in inadequate
luteal phase cycles. In these cycles, Day 1 is the first
day of menstrual flow and ovulation is presumed to
occur 14 days before the subsequent onset of
menses (Day 14). These three patterns can be
demonstrated simply by (1) charting menses and
seizures and (2) obtaining a mid-luteal phase serum
progesterone level to distinguish between normal
and inadequate luteal phase cycles (<5 ng/ml).
While the precise definition of catamenial epi-
lepsy remains arbitrary, one may maximize the
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seizure occurrence shows a high versus low degree
of hormonal sensitivity by using the points of inflec-
tion of the S-shaped distribution curves that define
the relationship between the severity of seizure
exacerbation and the number of women who have
exacerbation.4,7 These points are calculated to be in
the vicinity of a twofold increase in average daily
seizure frequency during the phases of exacerbation
relative to the baseline phases for all three types of
catamenial exacerbation. We propose the use of
these points of inflection values in seizure frequency
for the designation of catamenial epilepsy. By this
criterion, approximately one third of women with
intractable partial epilepsy would qualify for the
designation of having catamenial epilepsy.4,7 Adop-
tion of a standard albeit arbitrary nomenclature
may provide greater uniformity to study designs
for the investigation of the pathogenesis and treat-
ment of catamenial seizure exacerbation.Pathophysiology
There is considerable scientific evidence at mole-
cular biological, neuronal, experimental animal and
clinical levels to indicate that reproductive steroids
have neuroactive properties that play an important
role in the pathophysiology of epilepsy and the
pattern of seizure occurrence. Steroids act in the
brain by direct membrane-mediated (short latency)
effects as well as receptor-mediated genomically
mediated (long latency) effects.8—10Reproductive hormonal effects on
epilepsy
Estradiol
Estradiol exerts direct excitatory effects at the
neuronal membrane, where it augments N-
methyl-D-aspartate (NMDA) mediated glutamate
receptor activity.11,12 This enhances the resting
discharge rates of neurons in a number of brain
areas, including the hippocampus11—13 where estra-
diol increases excitability of the hippocampal CA1
pyramidal neurons and induces repetitive firing in
response to Schaffer collateral stimulation.12
Estradiol potentiates neuronal excitability by
regulating neuronal plasticity. It increases the den-
sity of spines and excitatory, NMDA receptor-con-
taining synapses on the apical dendrites of
hippocampal CA1 pyramidal neurons via a post-tran-
scriptional mechanism.14,15 The dendritic spine den-
sity on these neurons correlates positively with thelevels of circulating estradiol during the estrous
cycle of the rat and is decreased by oophorect-
omy.14,15 Estradiol may thus further increase exci-
tatory input to the CA1 neurons.
Estradiol may affect neuronal excitability by
cytosolic neuronal estrogen receptor-mediated,
genomically dependent mechanisms. Receptors
are particularly abundant in the temporolimbic sys-
tem, especially in the medial and cortical amygda-
loid nuclei, and occur in much fewer numbers in the
hippocampal pyramidal cell layer and the subicu-
lum.16,17 Estrogen receptor-containing neurons co-
localize with other neurotransmitters, including
gamma-amino-butyric acid (GABA).18,19 By regulat-
ing the expression of genes affecting the activity,
release and post-synaptic action of different neuro-
transmitters and neuromodulators, estrogens may
act to increase the excitability of neurons, which
concentrate estradiol. For instance, estradiol les-
sens inhibitory neurotransmission by decreasing
GABA synthesis in the corticomedial amygdala by
reducing the activity of glutamic acid decarboxy-
lase,20 and enhances brain epileptogenic muscarinic
neurotransmission by increasing choline acetyl
transferase and acetylcholine.21
In adult experimental animals, the thresholds of
limbic seizures in female rats fluctuate during the
estrus cycle inversely to estradiol levels.22 Physio-
logical doses of estradiol activate spike dis-
charges12,13,23,24 and lower the thresholds of
seizures induced by electroshock, kindling, penty-
lenetetrazol, kainic acid, ethyl chloride and other
agents and procedures.23—28 In fact, topical brain
application, as well as intravenous systemic admin-
istration, of estradiol in rabbits produces a signifi-
cant increase in spontaneous electrically recorded
paroxysmal spike discharges.24 The increase is seen
within a few seconds of application to suggest a
direct membrane rather than a genomic effect and
is more dramatic in animals with preexistent cor-
tical lesions.23,24 The role of estrogen, however,
may be more complex since there is also evidence
in some models that estradiol can raise seizure
thresholds in the hippocampal region and provide
neuroprotection against seizure-induced injury.29
Clinically, Logothetis et al.30 showed that intra-
venously administered conjugated estrogen clearly
activated epileptiform in 11 of 16 women and was
associated with clinical seizures in four.
Progesterone
Progesterone and particularly some of its neuroac-
tive metabolites, most notably allopregnanolone,
exert direct membrane-mediated inhibitory effects
by potentiating GABAA-mediated chloride conduc-
154 A.G. Herzogtance.9,31,32 It also potentiates the action of the
powerful endogenous inhibitory substance adeno-
sine.33 Progesterone itself also substantially
diminishes nicotinic acetylcholine receptor-
mediated conductance, which may be relevant to
autosomal dominant nocturnal frontal lobe epi-
lepsy.34
Progesterone may act via genomic mechanisms to
influence the enzymatic activity controlling the
synthesis and release of various neurotransmitters
and neuromodulators produced by progesterone
receptor-containing neurons.18 Progesterone binds
specific cytosolic receptors not only to produce its
own characteristic effects but also to lower estro-
gen receptor numbers and thereby antagonize
estrogen actions.35
Chronic progesterone decreases the number of
hippocampal CA1 dendritic spines and excitatory
synapses faster than the simple withdrawal of estro-
gen, counteracting the stimulatory effects of estra-
diol.14 Progesterone and allopregnanolone have also
been shown to have neuroprotective effects on
hippocampal neurons in kainic acid-induced seizure
models.36
In most adult female animal models, progester-
one depresses neuronal firing,37 and lessens sponta-
neous and induced epileptiform discharges.26—28,36—
38 It retards kindling and decreases seizure occur-
rence.26—28,36—38
Backstrom et al.39 found that intravenous infu-
sion of progesterone, sufficient to produce luteal
phase serum levels, was associated with a significant
decrease in interictal spike frequency in four of
seven women with partial epilepsy.
Neurosteroids
Most of the membrane effect of progesterone is due
to the action of its 3a-hydroxylated (i.e. A-ring-
reduced) metabolite, 3a-hydroxy-5a-pregnane-20-
one or allopregnanolone (AP).9,32 AP and the 3,5-
hydroxylated natural metabolite of the mineralo-
corticoid deoxycorticosterone, allotetrahydro-
deoxycorticosterone (allo-THDOC), are among the
most potent of a number of endogenous neuroactive
steroids with a direct membrane effect on neuronal
excitability.9,31,32 AP, but not allo-THDOC, is devoid
of hormonal effects and may, together with other
related neuroactive steroids, be thought of as an
endogenous regulator of brain excitability with
anxiolytic, sedative-hypnotic and anticonvulsant
properties.9,31,32 AP and allo-THDOC hyperpolarize
hippocampal and other neurons by potentiating
GABAA-mediated inhibition.
9,32 At physiological
(nanogram) with an extrasynaptic steroid-specific
site near the synaptic receptor to facilitate chloridechannel opening and prolong the inhibitory action of
GABA on neurons.9,31,32,40,41 At higher pharmacolo-
gical (micromolar) concentrations, AP also has a
direct effect at the synaptic GABAA receptor to
induce chloride currents.9,32 AP is one of the most
potent ligands of GABAA receptors in the CNS, with
affinities similar to those of the potent benzodiaze-
pine, flunitrazepam, and approximately a thousand
times higher than pentobarbital.9,32 The parent
steroid, progesterone, enhances GABA-induced
chloride currents only weakly and only in high con-
centrations.9,41 Plasma and brain levels of AP par-
allel those of progesterone in rats. In women,
plasma levels of AP correlate with progesterone
levels during the menstrual cycle and pregnancy.9
However, brain activity of progesterone and AP is
not dependent solely on ovarian and adrenal pro-
duction, as they are both synthesized de novo in the
brain.42 Their synthesis is region-specific and
includes the cortex and the hippocampus.42 By con-
trast, allo-THDOC is only synthesized by the adrenal
gland and not in the brain.9
AP, allo-THDOC and a number of other endogenous
and synthetic pregnane steroids have a potent anti-
convulsant effect in bicuculine-, metrazol-, picro-
toxin-, pentylenetetrazol-, pilocarpine- and kainic
acid-induced seizures and against status epilepticus,
but are ineffective against electroshock and strych-
nine-induced seizures.31,43—45 The anticonvulsant
properties of allopregnanolone resemble those of
the benzodiazepine and clonazepam.19,31,45 AP is less
potent than clonazepam butmay have lower relative
toxicity.44,45 The anticonvulsant effect of AP is
greater in female rats in the diestrus 1 part of the
ovulatory cycle (equivalent to human mid-luteal
phase when progesterone levels are high) than in
estrus (equivalent to ovulation when estrogen levels
are high) or in the male.40 Enhanced mid-luteal
efficacy at the GABAA receptor may be related to a
progesterone-induced enhanced formation of the d
GABAA receptor subtype.
40 Rapid withdrawal of pro-
gesterone in late diestrus makes the GABAA receptor
insensitive to benzodiazepine, but not AP, perhaps as
the result of a decrease in the benzodiazepine-sen-
sitive synaptic GABAA receptors.
46 This effect can be
blocked by inhibiting the formation of the a4 subunit
of the GABAA receptor.
40,46
By contrast, some of the sulfated neuroactive
steroids have excitatory neuronal effects. They
include pregnenolone sulfate and dehydroepian-
drosterone sulfate (DHEAS), the naturally occurring
sulfated esters of the progesterone precursor preg-
nenolone and progesterone metabolite DHEA.9
They increase neuronal firing when directly applied
to neurons by negatively modulating the GABAA
receptor9 and by facilitating glutamate-induced
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Table 1 Investigational sex hormone treatments of women with epilepsy
Investigational treatments Dosage Potential adverse effects
Progesterone lozenges Days 14—25: 1/2—1 lozenge t.i.d.
Days 26—27: 1/4—1/2 lozenge t.i.d.
Day 28: 1/4 lozenge t.i.d.
Sedation, depression, breast tenderness,
vaginal bleeding, constipation,
exacerbation of asthma, weight gain
Depomedroxyprogesterone 150—250 mg I.M. q 1—3 months As above plus delay of months to 2 years
in recovery of ovulatory cycles during
which time seizure numbers may increase
sometimes beyond baseline
GnRH analogue Leuprolide: 3.75 mg I.M. q 4 weeks
11.25 mg I.M. q 12 weeks
Menopausal symptoms unless concomitant
estradiol and progesterone supplement
is administered
Clomiphene Days 5—9: 25—50 mg daily Ovarian overstimulation syndrome
(N.B. distention of ovaries can be
very painful)excitation at the NMDA receptor.47 In animal seizure
models, pregnenolone sulfate and DHEAS have pro-
convulsant effect.48 Of note, serum DHEAS levels
are substantially reduced by enzyme-inducing anti-
epileptic drugs such as phenytoin and carbamaze-
pine.49,50Hormonal treatment
Progestogen therapy
The term ‘‘progestogen’’ refers to the broad class of
progestational agents. These include progesterone
(i.e. naturally occurring progesterone), and proges-
tins (i.e. synthetic progestational agents). Proges-
togen treatment (Tables 1 and 2) has taken two
forms: (1) cyclic progesterone therapy that supple-
ments progesterone during the luteal phase and
withdraws it gradually premenstrually and (2) sup-
pressive therapy in which the goal is to suppress the
menstrual cycle which is generally accomplished
using injectable progestins or gonadotropin-releas-





Regimen 5—10 mg q.d. Days
15—28 of cycle
100—200 mg t.i.d.
Days 15—28 of cycl








* p < .05.
** p < .01.Cyclic progesterone therapy
In contrast to published cyclic oral progestin inves-
tigations that did not result in significant reduction
of seizure frequency,51,52 two open label trials of
adjunctive progesterone therapy for women with
catamenial epilepsy did result in clinically impor-
tant and statistically significant reductions in sei-
zure occurrence (Table 2).53,54 In one investigation
of women who had inadequate luteal phase cycles
with catamenial exacerbation of intractable com-
plex partial seizures, six of eight women experi-
enced improved seizure control with a 68% decline
in average monthly seizure frequency over 3 months
for the whole group.53 In a subsequent open trial of
adjunctive cyclic progesterone versus the optimal
antiseizure medication alone in 25 women (14 with
inadequate luteal phase or anovulatory cycles and
11 with normal cycles and perimenstrual seizure
exacerbation), 19 (72%) experienced fewer seizures
with an overall average monthly decline of 54% for
complex partial and 58% for secondary generalized
seizures over 3 months.54 Progesterone was more






Days 15—28 of cycle
100—200 mg t.i.d.
Days 15—28 of cycle
at 3 months at 3 years
25 15 of original 25





156 A.G. Herzogsecond half of the cycle, rather than just premen-
strually, and then tapered and discontinued gradu-
ally over 3 or 4 days at the end of the cycle.54 Failure
to taper gradually premenstrually can result in
rebound seizure exacerbation. At 3 years, the aver-
age daily seizure frequency per patient showed that
the 15 women who remained on cyclic progesterone
therapy and their original antiepileptic drugs con-
tinued to show improved seizure control in compar-
ison to their own baseline (Table 2, 3-year follow-
up).55 Three women were entirely seizure-free.
Four had total seizure reductions of 75—99%. Eight
had reductions of 50—74%. Complex partial seizures
in these 15 were lower by a statistically significant
62% (baseline: 0.328, 3-year follow-up: 0.125;
p < .01); secondary generalized motor seizures,
by 74% (baseline: 0.148, 3-year follow-up: 0.038;
p < .01). Antiepileptic drug serum levels continued
to show no significant change. The three remaining
women who continued on progesterone therapy had
10—50% improvement at the end of the original
investigation at 3 months and were not considered
further because they changed antiepileptic drugs.
By way of critique, the weakness of these pre-
liminary progesterone investigations is that they
were not placebo-controlled or blinded. The favor-
able 3-year follow-up results are biased by analysis
of only 15 of the original 25 subjects. These 15 who
remained on the original treatment regimen are
more likely to represent those who had the most
favorable response. There are reasons, however, to
consider that the results of the present investigation
may represent more than placebo effects: (1) few
placebo studies, including our own progestin trial
that used a similar methodology, and could be used,
therefore, as a retrospective control, show favor-
able response in more than 50% of subjects; (2) few
placebo treatments have resulted in greater than
50% seizure reduction; (3) while placebo effects
generally wear off over a few months, substantial
and statistically significant improvements in the
present investigation persisted after 3 years in
the majority of subjects.55 Another argument
against the placebo explanation is that the bene-
ficial effect of progesterone can be eliminated by
the concomitant use of a reductase inhibitor that
presumably blocks the reduction of progesterone to
its potent GABAergic metabolite allopregnano-
lone.56 Finally, there is transcranial magnetic sti-
mulation evidence that progesterone may increase
inhibition in the brain premenstrually.57 A prospec-
tive multicenter, randomized, double-blind, pla-
cebo-controlled investigation of cyclic, adjunctive
progesterone therapy in the management of women
with catamenially exacerbated, intractable locali-
zation-related epilepsy is now under way.2,7Natural progesterone is available as an extract of
yams or soy in lozenge form in variable dosages
ranging from 25 to 200 mg and should be adminis-
tered three times daily because of its brief half-life
of about 4—6 h.53—55 The daily regimen to achieve
physiological luteal range serum levels measured 4 h
after administration ranges from 50 to 200 mg,
taken three times daily, with the usual optimal daily
dose ranging from 300 to 600 mg.53—55 The main-
tenance dosage and regimen should be individua-
lized and based on a combination of clinical
response and serum progesterone levels between
20 and 40 ng/ml. Progesterone is also available in
micronized form in an oral capsule preparation that
may also exert similar antiseizure effects although
formal investigations to this effect are lacking.
Theoretically, it is possible that first pass through
the liver using the oral micronized form may result
in the delivery of different concentrations of pro-
gesterone and its neuroactive metabolite to the
brain.
Adverse effects occur with overdosage and
include sedation, emotional depression and asthe-
nia.53—55 Progesterone use may also occasionally be
associated with breast tenderness, weight gain, and
irregular vaginal bleeding and sometimes constipa-
tion. The vehicle used to dissolve progesterone for
suppository use may rarely be responsible for the
development of an allergic rash. Discontinuation of
the hormone or lowering of the dosage resolves
these side effects.53—55
Drug interactions are an important consideration.
Higher progesterone dosages may be required to
achieve luteal range levels in women who take
antiseizure medications because carbamazepine,
phenytoin and barbiturates are known to enhance
the hepatic metabolism of gonadal and adrenal
steroid hormones as well as to increase hormonal
binding to serum proteins.56 Progesterone use has
been associated with changes in antiseizure medi-
cation levels in some cases but this effect has been
sporadic and not in a predictable direction. There-
fore, total and possibly free serum antiseizure med-
ication levels should be checked regularly during
concomitant hormonal therapy.
Progestin therapy
Parenteral depomedroxyprogesterone may lower
seizure frequency when it is given in sufficient
dosage to induce amenorrhea.52,58 In one open label
study of 14 women with refractory partial seizures
and normal ovulatory cycles, parenteral depome-
droxyprogesterone administration in doses large
enough to induce amenorrhea (i.e. 120—150 mg
every 6—12 weeks) resulted in a 39% seizure reduc-
Catamenial epilepsy 157tion.52 It was unclear whether the effect was due to
direct anticonvulsant activity of medroxyprogester-
one or to the hormonal consequences of the induced
amenorrhea. One patient who had absence rather
than partial seizures did not improve. Side effects
included those encountered with natural progester-
one. Depot administration, however, is also com-
monly associated with hot flashes, irregular
breakthrough vaginal bleeding and a lengthy delay
of 6—12 months in the return of regular ovulatory
cycles.52 Long-term hypoestrogenic effects on car-
diovascular and emotional status need to be con-
sidered with chronic use. Bone density is only
partially maintained.
Oral synthetic progestins administered cyclically
or continuously have not proven to be an effective
therapy for seizures in clinical investigations51,52
although individual successes with continuous daily




Bauer et al.60 used triptorelin, a synthetic gonado-
trophin-releasing hormone (GnRH) analogue
(3.75 mg) in a controlled release depot form intra-
muscularly every 4 weeks for an average of 11.8
months in 10 women (aged 20—50) with catamenial
seizures intractable to high therapeutic doses of
carbamazepine, diphenylhydantoin, phenobarbital
and valproic acid inmonotherapy or combined. They
remained on a stable dose of the anticonvulsant
throughout the period of treatment with triptorelin.
They reported that three patients became seizure-
free; four showed a decrease in seizure frequency of
up to 50%. In one the duration of seizures was
shortened; two had no therapeutic effect. These
results were attained within the first 2 months of
starting triptorelin. The study was not a controlled
study and longer term follow-up was not available
for some of the patients. Serum LH and estrogen
were measured in one patient before and during the
second month of triptorelin treatment; and as
expected showed marked inhibition of LH and estro-
gen production. All the women became amenor-
rheic. Eight of the ten patients experienced hot
flushes, headache or weight gain.
Haider and Barnett61 reported on their use of
goserelin 3.6 mg subcutaneously every 4 weeks in
a 41-year-old woman who had had frequent cata-
menial status epilepticus despite therapeutic antic-
onvulsant drug levels which also did not respond to
levonorgestrel/ethinyl estradiol. They reported a
decrease in frequency from 10 admissions for status
to three over a similar period.GnRH analogues basically create a medical
oophorectomy. Common side effects are flushing,
vaginal dryness and dyspareunia. Serious long-term
risks include osteoporosis and cardiovascular dis-
ease. Reid and Gangar62 suggested the addition of
medroxyprogesterone acetate and conjugated
estrogens to goserelin to prevent this while still
abolishing most of the cyclical fluctuations of ovar-
ian hormones. Finkelstein et al.63 recently discussed
the use of parathyroid hormone to prevent bone loss
in women treated with GnRH analogues. Although
neither Bauer et al.61 nor Haider and Barrett62
reported exacerbation of seizures with GnRH ana-
logues, Herzog64 found that during the first 3 weeks,
when there is an initial stimulation of estrogen
before its production is inhibited, some women
experienced such a marked exacerbation of their
seizures and auras that they could not tolerate
further use of GnRH analogue.References
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